GlassScriptPhysician profile
Akshay Bhatnagar
NPI 1407267511
$2,226.60
in general payments reported to CMS, 2019-2025
24 companies · $442 in 2025
The $442 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.67 · 2020: $109 · 2021: $590 · 2022: $186 · 2023: $479 · 2024: $403 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277 · Education: $46.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.19 |
| Education | $46.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $720.18 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $404.14 | 2020-2023 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $170.25 | 2021-2025 | Airsupra, Fasenra, Andexxa |
| Amgen INC. | $131.60 | 2024-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $100.27 | 2020-2025 | Cuvitru |
| Mylan Specialty L.P. | $92.02 | 2020-2023 | Yupelri |
| Grifols USA, LLC | $69.80 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Inspire Medical Systems, INC. | $63.15 | 2023 | Inspire |
| Pfizer INC. | $57.63 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.52 | 2019-2023 | |
| Verona Pharma, INC. | $52.88 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $51.96 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.18 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $32.14 | 2021 | |
| United Therapeutics Corporation | $24.32 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $22.09 | 2021 | |
| Optinose US, INC. | $21.58 | 2021 | |
| Abbvie INC. | $20.78 | 2024 | |
| Merck Sharp & Dohme LLC | $20.75 | 2024 | Recarbrio, Zerbaxa |
| Advanced Respiratory, INC | $18.36 | 2021 | |
| Vifor Pharma, INC. | $17.76 | 2024 | Zemaira |
| Inogen, INC. | $15.98 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Resmed Corp | $14.82 | 2024 | |
| Ambu INC. | $5.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akshay Bhatnagar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.